Novartis’s Early HTA Engagement Pays Off With Luxturna

 
• By Ian Schofield
  
Eye chart
Novartis explains why its vision loss gene therapy was OKd by NICE in record time
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Market Access